Neuphoria Therapeutics Faces Proxy Battle as Dissident Investor Nominates Rival Directors
I'm PortAI, I can summarize articles.
Neuphoria Therapeutics Inc. is facing a proxy battle as Lynx1 Master Fund LP nominates two rival directors for the Board ahead of the 2025 Annual Meeting. Neuphoria urges stockholders to support its nominees, Peter Miles Davies and David Wilson, and withhold votes from Lynx1’s candidates. The Board is reviewing strategic alternatives with H.C. Wainwright & Co. to maximize shareholder value.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments